<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00452803</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-06-164</org_study_id>
    <nct_id>NCT00452803</nct_id>
  </id_info>
  <brief_title>Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in N2 Positive IIIA Non Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Randomized Phase II Study Preoperative Chemotherapy Versus Preoperative Concurrent Chemoradiotherapy for Patients With Biopsy-Proven N2 Stage IIIA Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is suggested that a bimodal or trimodal approach combining neoadjuvant chemotherapy with
      or without radiotherapy followed by surgery provides a potentially superior method of
      enhancing resectability and improving locoregional control and survival compared to
      radiotherapy alone followed by surgery. Unsolved questions are the identification of the best
      induction strategy, the impact of surgery on long-term survival, and the contribution of
      radiation therapy in this setting. Thus, the investigators conduct a phase II trial to
      compare neoadjuvant chemotherapy with concurrent chemoradiotherapy in patients with biopsy
      proven N2 stage IIIA NSCLC to address optimal induction strategy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preoperative Therapy Arm 1. (preoperative chemotherapy) Paclitaxel (90 mg/m2)on day 1 and 8
      Cisplatin (40 mg/m2)on day 1 and 8. q 3 weeks, 2 cycles

      Arm 2. (preoperative chemoradiotherapy) Paclitaxel (50 mg/m2)on day 1, 8, 15, 22 &amp; 29
      Cisplatin (20 mg/m2)on day 1, 8, 15, 22 &amp; 29. Thoracic radiation therapy (TRT) 1.8 Gy daily,
      five times per week (45 Gy target dose in 5 weeks).

      Postoperative Consolidation Chemotherapy:

      Paclitaxel (90 mg/m2) on day 1 and 8. Cisplatin (40 mg/m2) on day 1 and 8. q 3weeks, 2 cycles
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2006</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate the time to recurrence</measure>
    <time_frame>The interval from the date of randomization to the date to the date of the first objective evidence of recurrence or to the date of death, if before recurrence</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To estimate the overall survival</measure>
    <time_frame>from the date of randomization to the date of death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the pathologic complete response rate and the complete resection rate</measure>
    <time_frame>After surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate toxicities</measure>
    <time_frame>from the first date of treatment to 30 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>study arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pre-operative chemotherapy (Pac/Cis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>study arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-operative concurrent chemoradiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>Paclitaxel 90mg/m2 + Cisplatin 40mg/m2 on D1 &amp; 8 q 3weeks, Pre-OP &amp; post-op : 2cycles (total 4 cycles)</description>
    <arm_group_label>study arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concurrent chemoradiation therapy</intervention_name>
    <description>Paclitaxel 50mg/m2 + Cisplatin 20mg/m2 on D1 &amp; 8 q 3weeks, Pre-OP &amp; post-op : 2cycles (total 4 cycles)</description>
    <arm_group_label>study arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Concurrent chemoradiation therapy</intervention_name>
    <description>Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx</description>
    <arm_group_label>study arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologic or cytologic diagnosis of non-small cell lung cancer.

          2. Presence of biopsy-proven N2 stage IIIA, according to the American Joint Committee on
             Cancer (AJCC), with none of the mediastinal lymph nodes &gt; 3 cm in largest diameter.

          3. Tumor amenable to surgical resection.

          4. At least one unidimensional measurable lesion meeting Response Evaluation Criteria in
             Solid Tumors (RECIST. 2000).

          5. No prior tumor therapy (surgery, radiotherapy, chemotherapy, immunotherapy, or any
             other type of tumor therapy).

          6. Performance status of 0-1 on ECOG scale.

          7. At least 18 years old.

          8. Patient compliance that allows adequate follow-up.

          9. Medical fitness of patients adequate for radical NSCLC surgery.

         10. Adequate organ function including the following:Adequate hematologic function: WBC
             count ≥ 4,000/uL, absolute neutrophil count (ANC) ≥ 1,500/uL, platelet count ≥
             100,000/uL, and hemoglobin ≥ 10 gm/dL.Adequate hepatic function: bilirubin ≤ 1.5 x
             UNL, ALT or AST ≤ 2.5 x UNL.Adequate renal function: creatinine ≤ 1.5mg/dL.

         11. Signed informed consent from patient or legal representative.12. Patients with
             reproductive potential must use an approved contraceptive method during and for 3
             months after the study. Females with childbearing potential must have a negative urine
             hCG test within 7 days prior to study enrollment.

        Exclusion Criteria:

          1. Concurrent administration of any other tumor therapy, including radiotherapy,
             chemotherapy, immunotherapy.

          2. Active uncontrolled infection.

          3. Serious concomitant disorders that would compromise the safety of patient or
             compromise the patient's ability to tolerate therapy.

          4. MI within preceding 6 months or symptomatic heart disease including unstable angina,
             congestive heart failure, or uncontrolled arrhythmia.

          5. Significant neurological or mental disorder.

          6. Second primary malignancy.

          7. Pregnant or nursing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heung Tae Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heung Tae Kim, M.D.</last_name>
    <phone>+82-31-920-1602</phone>
    <email>htkim@ncc.re.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center, Korea</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>411-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jae-Ill Zoo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jong Mog Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Moon Soo Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyun-Sung Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jin Soo Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ji-Youn Han, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kwan Ho Cho, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hong Ryull Pyo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bin Hwangbo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hee Seok Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyae Young Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geon Kook Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Moon Woo Seong, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kyeong-Man Hong, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Byung-Ho Nam, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tak Yun, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2007</study_first_submitted>
  <study_first_submitted_qc>March 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2007</study_first_posted>
  <last_update_submitted>July 9, 2010</last_update_submitted>
  <last_update_submitted_qc>July 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Heung Tae Kim</name_title>
    <organization>National Cancer Center, Korea</organization>
  </responsible_party>
  <keyword>Non small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

